Q2 2023

Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001477932-23-006071

Q2 2023 · 10-Q

Revenue

$19.64K

+22.7% vs Q2 2022

Net Income

-$923.55K

N/M vs Q2 2022

EPS, diluted—

Operating Income-$946,901N/M

Operating Cash Flowderived-$571,543N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$19.64K	$16.00K	$15.72K	$33.70K
Net Income	-$923.55K	-$1.32M	-$1.06M	-$738.48K
EPS Diluted	—	—	-$0.16	-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR